medigraphic.com

2011, Número 3

<< Anterior Siguiente >>

Rev Med MD 2011; 2.3 (3)


Inmunopatogenia de Lupus Eritematoso Sistémico

Soto-Vargas J

Idioma: Español
Referencias bibliográficas: 38
Paginas: 170-179
Archivo PDF: 564.84 Kb.


RESUMEN

El lupus eritematoso sistémico (LES) es una enfermedad autoinmune con una amplia variedad de anormalidades inmunológicas, clínicas y laboratoriales. El LES tiene un componente genético indiscutible, sin embargo, es generalmente aceptado que se requiere un factor ambiental como detonante para el desarrollo de la enfermedad. La anormalidad inmunológica fundamental en lupus es la pérdida de tolerancia a antígenos nucleares. Estudios en modelos animales con knock-out génica o transgénicos, nos han provisto de una base conceptual para el entendimiento de los defectos que llevan a la pérdida de tolerancia inmunológica. En general, estos defectos pueden ser clasificados dentro de tres amplias categorías: 1) aquellos que promueven la presentación de autoantígenos y la respuesta a restos apoptóticos de una forma inmunogénica; 2) aquellos que afectan la señalización de células B y/o T, resultando en estimulación anormal autorreactiva de los linfocitos; y 3) aquellos que promueven la supervivencia de linfocitos autorreactivos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Borchers, A. T., Naguwa, S., Shoenfeld, Y., & Gershwin, M. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010, 9(5), A277-287.

  2. 2.D'Cruz, D. P., Khamashta, M., & Hughes, G. Systemic lupus erythematosus. Lancet 2007, 369, 587-596.

  3. Rahman, A., & Isenberg, D. Systemic Lupus Erythematosus. N Engl J Med 2008, 358, 929-939.

  4. 4.Cheung, Y.-H., Loh, C., Pau, E., Kim, J., & Wither, J. Insights into the genetic basis and immunopathogenesis of systemic lupus erythematosus from the study of mouse models. Semin Immunol 2009, 21, 372-382.

  5. 5.Buyon, J. P., Petri, M., Kalunian, Kalunian, K., Grossman, J., Hahn, B., y otros. The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial. Ann Intern Med 2005, 142(12), 953-962.

  6. 6.Kim, W.-U., Min, S., Hwang, S., Yoo, S., Kim , K., & Cho, C. Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus. Clinical & Experimental Immunology 2010, 161(3), 453-458.

  7. 7.Deng, Y., & Tsao, B. genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 2010, 6, 683-692.

  8. 8.Castaño-Rodríguez, N., Diaz-Gallo, L.-M., Pineda-Tamayo, R., Rojas- Villarraga, A., & Anaya, J.-M. Meta-analysis of HLA-DRB1 and HLADQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmun Rev 2008, 7(4), 322-330.

  9. 9.Vargas-Alarcón, G., Salgado, N., Granados, J., Gómez-Casado, E., Martinez- Laso, J., Alcocer-Varela, J., y otros. Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility. Hum Immunol 2001, 62(8), 814-820.

  10. 10.Reddy, M., Velázquez-Cruz , R., Baca, V., Lima, G., Granados, J., Orozco , L., y otros. Genetic association of IRF5 with SLE in Mexicans: higher frequency of the risk haplotype and its homozygozity than Europeans. Hum Genet 2007, 121(6), 721-727.

  11. 11.Harley, I. T., Niewold, T., Stormont, R., Kaufman, K., Glenn, S., Franek, B., y otros. The Role of Genetic Variation Near Interferon-Kappa in Systemic Lupus Erythematosus. J Biomed Biotechnol 2010, 706825 .

  12. 12.Nath, S. K., Han , S., Kim-Howard, X., Kelly , J., Viswanathan , P., Gilkeson, G., y otros. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008; (40), 152-154.

  13. 13.The International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008, 40(2), 204-210.

  14. 14.Vuyyuru, R., Mohan, C., Manser, T., & Rahman, Z. The lupus susceptibility locus Sle1 breaches peripheral B cell tolerance at the antibody-forming cell and germinal center checkpoints. J Immunol 2009, 183(9), 5716-5727.

  15. 15.Krishnan, S., Chowdhury, B., & Tsokos, G. Autoimmunity in systemic lupus erythematosus: Integrating genes and biology. Semin Immunol 2006, 18(4), 230-243.

  16. 16.Duffau, P. Platelet CD154 potentiates interferon-α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Trans Med 2010, 47-63.

  17. 17.Price, S. Activated platelets as a target for SLE therapy? Nat Rev Rehumatol 2010, 613.

  18. 18.Hoffman, R. W. T cells in the pathogenesis of systemic lupus erythematosus. Clin Immunol 2004, 113, 4-13.

  19. 19.Colasanti, T., Delunardo, F., Margutti, P., Vacirca, D., Piro, E., Siracusano, A., y otros. Autoantibodies involved in neuropsychiatric manifestations associated with Systemic Lupus Erythematosus. J Neuroimmunol 2009, 212(2), 3-9.

  20. 20.Fukuda, M., Lo, S., de Alemeida, C., & Shinjo, S. Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus. Clin Rheumatol 2009, 28(3), 301-304.

  21. 21.Paz, M., González-Maglio, D., Pino, M., Ferrari, A., Weill, A., Nasswetter , G., y otros. Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity. Clin Rheumatol 2011, 30(2), 209-216.

  22. 22.Faust, T. W. Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms. Proc Natl Acad Sci 2010, 18569–18574.

  23. 23.Gono, T., Kawaguchi, Y., Kaneko, H., Nishimura, K., Hanaoka, M., Kataoka, S., y otros. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2011, 1-8.

  24. 24.Kaveri, S. V., Mouthon, L., & Bayry, J. Basophils and Nephritis in Lupus. N Engl J Med 2010, 363(11), 1080-1082.

  25. 25.Warde, N. Activated basophils exacerbate lupus nephritis by amplifying production of autoreactive ige. Nat Rev 2010, 6, 438.

  26. 26.Charles, N., Hardwick, D., Daugas, E., Illei, G., & Rivera, J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med 2010, 16(6), 701-708.

  27. 27.Ye, J., Bromage , E., Kaattari, I., & Kaattari, S. Transduction of binding affinity by B lymphocytes: A new dimension in immunological regulation. Dev Comp Immunol 2011, Epub ahead of print.

  28. 28.Grommé, M., & Neefjes, J. Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol 2002, 39(3), 181-202.

  29. 29.Yoshimoto, K., Setoyama, Y., Tsuzaka, K., Abe, T., & Takeuchi, T. Reduced Expression of TCR Zeta Is Involved in the Abnormal Production of Cytokines by Peripheral T Cells of Patients with Systemic Lupus Erythematosus. J Biomed Biotechnol 2010, Epub pii 509021.

  30. 30.Barreto, M., Ferreira , R., Lourenço , L., Moraes-Fontes , M., Santos , E., Alves , M., y otros. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGF gene variants. BMC Immunol 2009, 10(5).

  31. 31.Hikada, M., & Zouali, M. Multistoried roles for B lymphocytes in autoimmunity. Nat Immunol 2010, 11(12), 1065-1068.

  32. 32.Peng, S. L. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev 2009, 8(3), 179-183.

  33. 33.Pan, Y., & Sawalha, A. Epigenetic regulation and the pathogenesis of systemic lupus erythematosus. Transl Res 2009, 153(1), 4-10.

  34. 34.Strickland, F. M., & Richardson, B. C. The epigenetics of autoimmunity: DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 2008, 41(4), 278-286.

  35. 35.Tsukumo, S.-i., & Yasutomo, K. DNaseI in pathogenesis of systemic lupus erythematosus. Clin Immunol 2004, 113(1), 14-18.

  36. 36.Beebe, A., Cua, D., & de Waal, M. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 2002, 13(4), 403-412.

  37. 37.Gómez, D., Correa, P., Gómez, L., Cadena, J., Molina, J., & Anaya, J.-M. Th1/Th2 Cytokines in Patients with Systemic Lupus Erythematosus: Is Tumor Necrosis Factor alfa Protective? Semin Arthritis Rheum 2004, 33, 404- 413.

  38. 38.Nagy, G., & Perl, A. The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus. Clin Immunol 2006, 145-151.




2020     |     www.medigraphic.com